Asabys portfolio company Orikine Bio appointed Larry Edwards as Chairman of its Board of Directors.
Orikine Bio is pioneering the development of precision-engineered, bi-specific cytokines to treat autoimmune and inflammatory diseases using its innovative Foldikine™ platform, which reprograms immune system signals to restore proper function
Orikine Bio is pioneering the development of precision-engineered, bi-specific cytokines to treat autoimmune and inflammatory diseases using its innovative Foldikine™ platform, which reprograms immune system signals to restore proper function.